Patients As Partners

  • Start Date:

    20 Mar 2023

  • End Date:

    23 Mar 2023

  • Location:

    Washington, DC

  • Region:

    North America

  • Booth #:

    22

Explore how to advance your drug development with patient centric solutions from PPD, part of Thermo Fisher Scientific:

  • Patient experience embedded into trials and the entire product lifecycle
  • Decentralized clinical trials that meet patients where they are—saving time and money
  • Real-world data that promotes drug development, regulatory approval and market growth
  • Custom suite of tools and technologies with direct input from thousands of patients
  • Engaging patients as partners throughout the clinical trial

Toward a systematic and integrated approach to patient partnering for patient-centric clinical trials

Monday, March 20 | 2:55 – 4:40 p.m.

 

What you will learn from the talk:

  • Operationalizing guidelines for quality patient engagement in practice
  • Integrating patient engagement and insights for study-wide application
  • Optimizing multi-stakeholder value and impact of patient engagement in clinical trials
Photo of Kevin Marsh, Vice President of Patient Centered Research (PCR). PPD, part of Thermo Fisher Scientific
SPEAKER

Kevin Marsh, Vice President of Patient Centered Research (PCR). PPD, part of Thermo Fisher Scientific

Kevin is Vice President of Patient Centered Research (PCR) at PPD, part of Thermo Fisher Scientific. PCR has over 130 scientists dedicated to the integration of the patient’s experience into product development. Kevin specializes in the use of patient preference data to inform health decisions, including pipeline optimization, trial design, authorization, reimbursement, and prescription decisions. He is a thought leader in the use of patient preference data; he is currently co-chairing the ISPOR Health Preference SIG, and has co-chaired taskforces and working groups for ISPOR. He recently led the development of StudyGage, a preference-data based tool allowing sponsors to simulate participation rates in clinical studies.